Viking Therapeutics (VKTX) Enterprise Value (2014 - 2026)
Viking Therapeutics (VKTX) posted Enterprise Value of -$501.7 million for Q2 2026, up 16.8% sequentially from -$603.0 million in Q1 2026, and up 37.89% YoY from -$363.8 million in Q2 2025.
Viking Therapeutics (VKTX) Enterprise Value (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Enterprise Value for 13 years, with the latest figure at -$501.7 million in Q2 2026.
- Quarterly Enterprise Value rose 37.89% year-over-year to -$501.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$501.7 million (up 37.89% YoY) and the FY2025 annual result came in at -$705.7 million, up 21.81% from the prior year.
- Enterprise Value improved to -$501.7 million in Q2 2026 per VKTX's latest filing, from -$603.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$135.7 million in Q1 2023 and troughed at -$963.0 million in Q1 2024.
- A 5-year average of -$564.3 million and a median of -$552.3 million in 2026 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 61.35% in 2023, then tumbled 609.82% in 2024.
- Over 5 years, Enterprise Value stood at -$155.5 million in 2022, then sank by 132.87% to -$362.1 million in 2023, then plunged by 149.29% to -$902.6 million in 2024, then increased by 21.81% to -$705.7 million in 2025, then climbed by 28.92% to -$501.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$501.7 million, -$603.0 million, and -$705.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | -501.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -501.66 Mn |
| Mar 31, 2026 | -602.96 Mn |
| Dec 31, 2025 | -705.74 Mn |
| Sep 30, 2025 | -714.57 Mn |
| Jun 30, 2025 | -807.72 Mn |
| Mar 31, 2025 | -851.86 Mn |
| Dec 31, 2024 | -902.61 Mn |
| Sep 30, 2024 | -930.44 Mn |
| Jun 30, 2024 | -942.26 Mn |
| Mar 31, 2024 | -962.98 Mn |
| Dec 31, 2023 | -362.08 Mn |
| Sep 30, 2023 | -376.24 Mn |
| Jun 30, 2023 | -392.92 Mn |
| Mar 31, 2023 | -135.66 Mn |
| Dec 31, 2022 | -155.49 Mn |
| Sep 30, 2022 | -155.02 Mn |
| Jun 30, 2022 | -305.38 Mn |
| Mar 31, 2022 | -351.05 Mn |
| Dec 31, 2021 | -202.10 Mn |
| Sep 30, 2021 | -216.14 Mn |